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ABSTRACT

THE COST-EFFECTIVENESS OF THE KENTUCKY PILOT PROJECT OF
ALLOWING PRIMARY PCI AT HOSPITALS WITHOUT ONSITE CABG
CAPABILITIES
Pedro G. Ramos
November 23 rd , 2010
A myocardial infarction (MI) occurs when blood supply to the heart is cut off by a
blockage in one of the coronary arteries. Most hospitals treat a patient with thrombolysis
or a percutaneous coronary intervention (PC I). The latter has been established as the
preferred revascularization method. However, the American College of Cardiologists and
the American Heart Association strongly recommend that a hospital performing PCI must
also have coronary artery bypass graft capabilities (CABG). By following these
recommendations, the state of Kentucky has limited the number of hospitals allowed to
perform PCI and thereby limiting access to such a life-saving procedure.
Recently, the state of Kentucky has begun evaluating if hospitals without such
capabilities should be allowed to perform primary PCI, and data from this evaluation
allowed the establishment of the medical soundness of allowing such hospitals to perform
primary PCI. To have the most comprehensive understanding of the effects of allowing
hospitals without surgical-backup performing primary PCI, the effects and costs must be
evaluated simultaneously. The current study aims to
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study the financial feasibility of allowing these hospitals to do emergency PCI in addition
to hospitals with onsite open-heart surgery capabilities.
The estimates have been derived from a systematic literature review of national
studies based on PCI registries as well as our earlier study - KENTUCKY PILOT
PROJECT FOR PRIMARY PCI WITHOUT ONSITE CABG. Costs estimates were
derived from the National Inpatient Sample, which approximates a twenty percent sample
of the U.S. community hospitals. In determining costs, the sample was extracted by
filtering using ICD-9 codes. A deterministic model was developed so that more
uncertainty would not be introduced. The economic evaluation focused on estimating the
incremental cost effectiveness ratio (lCER) of allowing regional hospitals to perform
primary PCI from a payer's perspective. Uncertainty about the model parameters was
investigated through employing sensitivity analysis techniques.
The study found that there were no statistically significant differences in
outcomes between hospitals with and without CABG capabilities. The only
characteristic, which was significantly different between these two groups, was total
charges. The alternative to allow Regional Hospitals as well to perform primary PCI
dominated the other alternative of Only Allowing Hospitals with Onsite CABG to perform
PCl. That is, allowing regional hospitals to perform primary PCI both incur fewer costs
while also averting more deaths. However, sensitivity to the cost of PC I at regional
hospitals was observed in the model. The study suggests that by allowing primary PCI to
be performed at selected facilities without onsite CABG, the state of Kentucky can
expand access to PCI and reduce geographical health disparities, one of its main
healthcare initiatives.
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CHAPTER I
INTRODUCTION

For individuals experiencing a myocardial infarction (MI), commonly
referred to as a heart attack (1), a trip to an emergency department to have the
blocked artery quickly opened by inflating a small balloon and inserting a tiny
metal structure called a stent that acts as permanent scaffolding is lifesaving. In
these emergency situations, the above procedure is termed primary
Percutaneous Coronary Intervention (PCI) (2). This is contrasted to elective PCI
in which PCI is performed prior to a heart attack. Restoring blood flow to the
heart muscle as quickly as possible is truly a benefit to the patient. The American
College of Cardiology, the American Heart Association and the Society for
Cardiovascular Angiography and Interventions strongly recommend that primary
PCI should only be performed in facilities that have an experienced
cardiovascular surgical team available as emergency backup for all procedures
(3).
Recently, the State of Kentucky has begun evaluating if hospitals without
such capabilities should be allowed to perform primary PCI. As a result, data
from this evaluation allowed our research team to establish the medical
soundness of allowing such hospitals to perform primary PCI (4); our results
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suggest that hospitals without surgical backup capabilities achieved similar
outcomes as hospitals with surgical backup capabilities for all studied outcomes
(mortality, door-to-balloon time, cardiac arrests and emergency surgeries as a
result of the PCI). However, in order for health interventions to be incorporated
effectively, both the effectiveness and the costs must be evaluated
simultaneously. That is, to have the most comprehensive understanding of the
effects of allowing hospitals without backup surgical capabilities performing
primary PCls the effects and costs must be evaluated simultaneously (5, 6).
Myers et al.'s initial study failed to include costs in the analysis. Therefore, the
current study investigates the costs associated with allowing hospitals without
onsite Coronary Artery Bypass Graft surgery (CABG) capabilities to perform
primary PCI in the State of Kentucky. As such, combing the current study with
our earlier results allows us to calculate an incremental cost-effectiveness ratio to
investigate the cost-effectiveness of this pilot program and established whether it
is financially feasible to perform primary PCI at hospitals without backup surgical
capabilities.

Myocardial Infarction
A heart attack or myocardial infarction (MI) occurs when blood supply to
the heart is disrupted by an occlusion in one or more of the coronary arteries.
This deprivation of blood to the heart muscle causes damage or possibly death to
the heart's tissues known as myocardium (7). It is been well established that the
longer the heart is deprived of blood, the more heart muscle is damaged and
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killed. The axiom cardiologist have is that time saved is heart saved; thus,
establishing the need to open the coronary arteries occluded as quickly as
possible (2).
Some of the symptoms of a heart attack are chest pain or angina,
shortness of breath, profuse sweating, burning sensation in the esophagus, and
radiating pain to the arms and legs, especially on the left side of the body.
Individuals who have previously been diagnosed with cardiovascular disease are
aware of these symptoms and know that they must manage the pain with
nitroglycerin and aspirin (2, 8, 9). Since these symptoms are also common
symptoms of less severe illnesses (e.g., heartburn) it is not recommended that
an individual seek medical attention unless the pain does not subside within five
minutes. Then the individual should visit an emergency department to alleviate
their pain and receive treatment.

Diagnosis of a MI
Once a patient is at the emergency department, emergency personnel will
follow a well established and studied algorithm to determine if the individual is
experiencing a MI. Nonetheless, emergency departments routinely begin
treatment for an MI, believing a false-positive (treating a MI while the patient truly
has, for example, heart burn) is a less severe mistake to make than a falsenegative (treat for heart burn while the patient is experiencing aMI) (10).
The patient (and/or their relatives) will be asked several questions
concerning the patient's medical history to determine their risk of a heart attack.
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In addition, a series of diagnostic tests will be conducted immediately upon
arrival to the hospital: electrocardiogram, blood test, and echocardiogram. The
electrocardiogram (ECG) and echocardiogram (ECHO) are usually performed in
tandem. While an electrocardiogram assess the electrical activity of the heart, an
echocardiogram uses ultrasound to produce images of the heart structures. The
benefits of these tests will be discussed below, but the results of these tests
allow cardiologists to determine the exact type of MI a patient is experiencing
(e.g., STEMI). The most definitive test to establish if a MI is occurring is the
confirmatory blood tests. The human body only produces changes in the levels of
the enzymes troponin and creatine kinase if the heart muscle has recently been
damaged. Therefore, if these enzymes show in the blood test, it is very definitive
that a MI has occurred (10).

STEMI
One of the least predictable and most severe heart attacks is classified as
ST-elevated myocardial infarction (STEMI). It is caused by sudden clots, known
as thrombotic occlusions, in the coronary arteries which had not experienced any
narrowing previously (11). They are indicated by the electrocardiogram (ECG)
that is performed upon admission to the emergency department when the ECG
displays an abnormal elevation in the "ST segment" of the electrical heart wave.
STEMI is considered the most severe type of heart attack because it is caused
by a complete occlusion of one of the coronary arteries. The less blood flows
into the heart and the longer the diminished flow lasts, the greater the damage to
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the heart muscle (myocardium) and the less likely the patient will recuperate.

Treatment of STEMI
Currently, there are three options to treat patients experiencing a STEMI
heart attack: (1) thrombolysis, (2) percutaneous coronary intervention (PCI), also
known as balloon angioplasty, and (3) coronary artery bypass graft surgery
(CABG) if three or more occlusions have occurred (8, 9, 11).
Thrombolysis consists of injecting the patient with clot-diluting drugs in
order to open the blocked artery. However, thrombolysis has been considered a
less effective and less efficacious reperfusion technique since it takes an
extended amount of time to begin to work (3, 8). By the time thrombolysis dilutes
the clot, too much of the myocardium is dead or damaged severely.
Thrombolysis was the first strategy developed to combat occlusions. However,
more recently, PCI has been repeatedly shown in numerous differing populations
to be more effective and efficacious when compared with thrombolysis, in
preserving more of a patient's myocardium. PCI has shown to have superior
clinical outcomes such as lower mortality rates, lower rates of recurrence of
thrombotic occlusion, lower rates of re-infarction, and shorter recovery times to a
productive life (11-15).

PCI Procedure
PCI (emergency angioplasty) is performed in a series of steps with slight
variations for an individual case. Once the patient presents at the emergency
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facility, the patient is treated with a fibrinolytic agent unless contraindicated by
the patient's clinical condition such as ventricular arrhythmias or cardiogenic
shock (2, 3, 8, 16, 17). Subsequently and immediately an angiogram is
performed. During an angiogram, a catheter is inserted into one of the femoral
arteries (located in the groin/thigh) and guided to the coronary arteries. The
femoral arteries are the largest arteries in the body. Injuries to the femoral artery
used can result very rapidly in severe blood loss and possible death; thus, the
need for PCI's to be performed by experienced surgeons, well-staffed and
experienced catheter labs, and at well-equipped facilities. A contrasting
substance is then injected into the vessel to make the area surrounding the heart
clear in the X-ray images. It is this tool that allows the emergency personnel to
determine what vessels are blocked. After the affected area has been
determined, a balloon catheter is inserted and guided to the blocked vessel.
Once in place, the balloon is inflated to open out the walls of the blood vessel
and crush the clot. Also, it is recommended to place a tubular mesh, know as a
stent, in the affected segment of the blood vessel to prevent the collapsing of the
vessel's walls. Finally, the catheter is often removed and the entry-puncture
sealed; or the catheter may be left in place up to twelve hours depending on the
length of time needed to thin the patient's blood. After successful angioplasty,
most patients are discharged within 24 hours of the procedure.
One key aspect for PCI to be successful is the door-to-balloon time (DTB)
(16, 18-22). This is the length of time between the patient arriving at the
emergency facility and the moment the balloon is inflated in the affected segment
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of a blood vessel. After many clinical studies, it has been determined that the
DTB should be less than 90 minutes. The reason for this timeframe is that it
provided, in multiple clinical trials, lower in-hospital death rates, reduced 30-day
mortality rates, shorter average lengths of stay in the hospital, lower rates of
reinfarction, and lower rates of reocclusion (18, 20, 22-24).

Issue with Primary PCI at hospital without onsite CABG Capabilities
An inherent risk to performing primary PCI is accessing or puncturing the
femoral artery, which is a large artery, and may lead to a patient "bleeding out"
very fast and leading to the patient's death if not corrected quickly. Also, issues
may arise during the procedure such as an abrupt closure of the previously
opened artery. In addition, patients with elevated risks for MI and other comorbidities may need to be transferred to an operating room that is capable and
equipped to perform open-heart surgeries. Therefore, it is recommended that
facilities performing PCI's should have appropriate onsite back-up surgical
capabilities (3).
The decision to allow hospitals without CABG capabilities to perform
primary PCI rests on each state's regulatory body. While the American College
of Cardiology/American Heart Association (ACC/AHA) guidelines give primary
angioplasty without surgical backup a class 2b indication ("probably reasonable"),
30 states currently allow hospitals without surgical open heart surgery (SOS)
capabilities to perform primary (emergency) PCI. A myriad of studies, mostly
retrospective, have shown that no difference in clinical outcomes exists between

7

hospitals with CABG capabilities and hospitals without surgical backup for
primary PCI (4, 23, 25-31).
Since, in the state of Kentucky, most cases of heart attack seem to
originate in rural areas and the state of Kentucky did not permit the delivery of
primary PCI in hospitals without surgical backup, a three-year pilot study to
assess the soundness of allowing select facilities in Kentucky to perform primary
PCI despite lacking onsite surgical backup was implemented in 2005 (4). It
involved two regional hospitals without onsite CABG capabilities: T.J Samson
Community Hospital in Glasgow, Ky and Ephraim McDowell Regional Medical
Center in Danville, Ky. This study concluded that there was no significant
difference in any of the clinical outcome between facilities with and without
emergency backup capacity. Recommendations from this study included the
revision of the ACC/AHA guidelines for primary PCI by allowing hospitals without
backup open-heart surgical capabilities to perform emergency PCI with
restrictions on surgeon's experience, catheterization lab team training, and
facilities volume.

Current Study
By incorporating the costs associated with the pilot program in addition to
the effectiveness of the program, a Cost Effectiveness Analysis (CEA) can be
executed to evaluate the cost-effectiveness of allowing hospitals without onsite
CABG capabilities to perform primary PCI. Therefore, the current study alludes
to the financial feasibility of allowing these hospitals to do emergency PCI in

8

addition to hospitals with onsite open-heart surgery capabilities.
Specifically, the current study focuses on the cost-effectiveness of
allowing select facilities in Kentucky to perform primary PCI despite lacking
onsite surgical backup capabilities, when compared to only allowing hospitals
with back-up surgical capabilities to perform primary PC. In addition, the current
study discusses further potential savings in costs due to such effects as shorter
hospital length of stays, transfer costs, readmission costs, and possibly the
decrease in coronary heart failure (CHF) care that may materialize with a welltimed reperfusion.
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CHAPTER II
LITERATURE REVIEW

Myocardial infarction (MI), also known as a heart attack, is the damage or
possible death that the specialized heart's tissue known as the myocardium
experiences when blood supply to the heart is blocked (10). MI can be classified
in five types:
•

Type 1: spontaneous and related to ischemia due to a coronary event.

•

Type 2: secondary to ischemia due to an imbalance between oxygen
demand and supply.

•

Type 3: sudden cardiac death with symptoms of ischemia and new 8T
elevation or LBBD, verified thrombus by angiography, or autopsy.

•

Type 4a: associated with previously performed PCI.

•

Type 4b: associated with verified stent thrombosis.

•

Type 5: associated with CABG.

However, for practical purposes, and in clinical settings, a MI is classified
from based on results from an electrocardiographic diagnostic test that assesses
the heart's various electrical waves to determine the precise site of the infarction

(7,9):
•

Inferior (or diaphragmatic) wall: II, II and aVF
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•

Septal: V1 and V2

•

Anteroseptal: V1, V2, Vf3 and sometimes V4

•

Anterior: V3, V4 and sometimes V2

•

Apical: V3, V4 or both

•

Lateral: I, aVL, V5 and V6

•

Extensive anterior: I, aVL and V1 through V6

According to the ECG reading the severity of the MI can also be determined
as either STEMI, the most severe, or NSTEMI (2). STEMI will display an
elevation in the ST segment of the T-wave, which represents a total occlusion of
a coronary artery.
Development of Thrombolytic Therapy
Thrombolytic or fibrinolytic therapy was originally studied and developed in
the 1950's with promising results by Dr. Sol Sherry who demonstrated that
streptokinase could dissolve blood clots that typically occluded coronary arteries.
However, more recent reperfusion theory demonstrates that thrombosis is a
secondary event in ischemic events. Long after the advance that a coronary
occlusion was an etiology of acute myocardial infarction, the Gruppo Italiano per

10 Studio della Streptochinasi nell'lnfarcto miocardio (GISSI) study (in 1986)
established through a multicenter randomized clinical trial that in-hospital
mortality was reduced by more than 3% following streptokinase administration
(8). Yet, streptokinase and other first generation thrombolytic agents came with
the limitation of being immunogenic and with a third of the patients receiving
therapy being unresponsive to such therapy. DNA research advances led to
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fibrin specific plasminogen activators, which resulted in much lower rates of
mortality and risk reduction when compared to streptokinase to treat AMI leading
to extended hope for thrombolysis. Similarly, aspirin demonstrated similar
survival benefits to those of streptokinase alone in several clinical trials.

Development of Percutaneous Coronary Intervention
PCI, or angioplasty, was developed in 1977 when the Swiss radiologist
Andreas Gruentzig performed the first percutaneous transluminal coronary
angioplasty on a thirty-eight year old patient with a left coronary artery lesion
(17). Compared to today's equipment, the catheters were large and could easily
injure a blood vessel. In addition, no guidewires were used and balloon
catheters would discharge suddenly at low pressure levels. This rendered this
type of intervention available to only ten percent of patients needing
revascularization. Fortunately, during the early 1908s, the catheters were
manufactured smaller and balloons were designed to inflate at higher pressures,
which made balloon angioplasty available to nearly 50% of patients in need of
revascularization. However, one of the drawbacks of balloon angioplasty is that
it fractures plaque that is causing the current occlusion. The fissured atheroma
may cause the formation of a new thrombus later. Another limitation is the
weakening of the vessel which may cause the vessel to recoil resulting in
restenosis. As a result, new devices aimed to combat these limitations were
developed and manufactured. The transluminal extraction catheter and excimer
laser enabled the development of atherectomy, although they were not
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associated with a reduction in the incidence of restenosis rendering these
instruments as niche tools. It wasn't until the advent of coronary stents in 1986
that PCI was shown to be safe and more effective by significantly reducing
restenosis. Improvements to stents such as pharmacologic coating and various
levels of flexibility and strength followed in the 1990s and the first decade of the
twenty-first century.
Effectiveness of PCI
Several clinical trials have been conducted to investigate the effectiveness
of PCI compared to adjunctive therapy in NSTEMI patients. A key idea in these
results was the stratification of the patients according to the Thrombolysis
Myocardial Infarction (TIMI) score, which classifies patients as high, medium, or
low risk. High-risk patients, with TIMI scores of five or greater, are those with
three or more of the following characteristics: prolonged chest pain, hypotension,
65-years of age or older, ST-segment changes, and elevated biomarkers levels
(32). Retrospective stUdies based on the Global Registry of Acute Coronary
Events (GRACE) and the Euro Heart Survey of Acute Coronary Syndromes
found that the proportion of patients with an admission diagnosis of unstable
angina or MI quickly progress to NSTEMI (24% and 21 % respectively) or to
STEMI (6% and 69% respectively) (16, 33). These two studies also found that
hospitals with a catheterization lab treat 53% (in the US) and 25.4% (in Europe)
of patients with a diagnosis of NSTEMI with PCI. Researchers from the clinical
trial TIMIIIIB (34), found three significant independent predictors of late positive
troponin, a confirmatory biomarker for MI, (1) levels for patients presenting with
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ACS and early negative troponin levels: TIMI 3 (OR=3.52, 95% CI = 2.38-5.23,
p<0.001), (2) ST-deviations (OR=2.91 , 95% CI =1.92-4.40, p<.001), and (3) no
prior use of beta blockers (OR=1.74, 95% CI=1.15-2.63, p=.008). For patients
with a high-risk score, most studies have found that an early aggressive
reperfusion therapy, PCI or CABG, resulted in better clinical outcomes when
compared to a conservative therapy of pharmacologic agents (table 1). In FRISC
II, a clinical trial comparing early invasive with non-early invasive strategies at
one year follow-up found that the composite outcome of death or MI occurred in
10.4% of those in the early invasive arm and 14.1 % of those in the non-early
invasive arm with a p-value of 0.015 (35). A new meta-analysis by Dr. Keith Fox
found that an aggressive approach leads to better long-term outcomes when
compared to a more selective conservative strategy (table 2) (36). The decision
between PCI and CABG is primarily based on anatomical and physiological
characteristic of the injury. For example: left main coronary artery disease,
compromised left ventricular function, diabetes, and/or three or more vessel
injuries are treated with CABG, while two or fewer vessel injuries are reperfused
with PCI (32).
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Table 1. 30-day and 6-month mortality rates stratified by aggressive and conservative therapy.
30 - days
Study

6 - Months

Aggressive
Therapy

Therapy

Aggressive

Conservative

Therapy

Therapy

NA

NA

1.96

Neumann

5.9%

et al,37

11.6%

(1.01,3.82)

NA

p=0.025
.67 (.5,
7.4%

10.5%

.91)

.78 (.62,
15.9%

19.4%

p=0.009

.97)
p=0.025
.54 (.4,

Morrow
7.4%

et al,39

15.3%

16.2%

25%

.73)
p<0.001

Table 2. Cox regression of outcomes stratified by selective and routine invasive procedures .
Outcomes

Selective Invasive

Routine Invasive

Hazard Ratio

p-value

10.0%

0.77

.001

MI
CV death

8.1%

6.8%

0.83

.068

CV death/MI

17.9%

14.7%

0.81

.002

11.7%

10.6%

0.90

.190

20.9%

18.1%

0.85

All-cause mortality
All-cause mortality/MI

Similarly, a myriad of clinical studies and retrospective studies based on
registries have been conducted to investigate the difference in clinical outcomes
between primary PCI and thrombolytic therapy. A vast majority of the studies
have concluded that PCI resulted in better long-lasting outcomes when
compared with fibrinolytic therapy (table 3). In a small trial by Zijlstra, tests for
differences in unconventional outcomes that relate to an individual's long-term
functioning were performed showing those managed with PCI had less unstable
15

angina (5.7% vs. 19.4% p=0.02), more left ventricular ejection (51 vs. 45
p=0.004) and more patency in the related artery (91 vs. 68 p=0.001) (15).
Likewise, GUSTO lib analysis concluded that PCI was superior to thrombolytic
therapy. In 30-day follow-ups, a composite outcome of death, non-fatal
reinfarction, and disabling stroke was measured in patients randomized to PCI
and thrombolysis showing PCI's superiority in this composite outcome (9.1 % vs.
13.7%, p=0.013). DANAMI-2 clinical trial also showed that PCI was superior to
fibrinolytic therapy when it was stopped in the second interim study with a pvalue less than 0.009 in favor of PCI (40). Furthermore, the advent of stents and
drug-eluting stents has resulted in superior outcomes in the latest trials and PCIregistry analyses (32). In a meta-analysis comparing randomized clinical trials of
primary PCI versus Thrombolysis, researchers found that the odds ratio of
mortality at six weeks was 0.56 (0.33, 0.94) demonstrating that PCI was
favorable (41). A key aspect of these studies is the time to reperfusion
subsequent to hospital admission. The optimal time to reperfuse via PCI
technique has been determined to be 90 minutes or less (3). For instance, a
cohort study based on the American College of Cardiology National Data
Registry indicated that longer door-to-balloon times were associated with higher
risk of mortality in hospitals (24). The risk of in-hospital mortality increased from
3.0% with a 30-minute door-to-balloon time to 8.4% with a door-to-balloon time of
180 minutes in non-linear fashion and with a p-value less than 0.001.
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Table 3
In-hospital
Authors

6 - Months / 1 - Year

Outcomes
PCI

Thrombolysis

PCI

Thrombolysis

p-value

value
Grines et
al.

21

Zijlstra et
al.

2.6%

6.5%

0.06

NA

NA

NA

Reinfarction

5.1%

12.0%

0.02

8.5%

16.8%

0.02

Death

0.0%

6.0%

0.13

NA

NA

NA

12.5%

0.003

NA

NA

NA

5.5%

0.6

3.6%

7.3%

0.7

45.5%

0.0001

15

Ribichini
et al.

14

Le May et
al.

Death

42

Schoming
et al. 43

Death

1.8%

Reinfarction

9.1%

Death

4.8%

3.3%

1.0

4.8%

3.3%

1.0

Reinfarction

11.3%

42.6%

0.001

14.5%

49.2%

0.001

Death

NA

NA

NA

8.5%

23.2%

Reinfarction

NA

NA

NA

10%

34.9%

PCI at hospitals without onsite surgical backup
Many of the retrospective studies based on registries have found that many
cases of MI originate in rural areas where most hospitals lack open-heart surgery
capabilities (23, 28 , 30). Between 1998 and 2002, Alamance Regional Medical
Center offered primary PCI under the guidance of Duke University Medical
Center as part of a pilot program (28). The inclusion criteria were those of low to
moderate-risk patients according to the literature. A total of 561 interventions
were performed with a success rate of 98%, adverse events included: one death
due to acute renal failure after successful PCI, while the other 2% of the patients
were transferred to Duke Medical Center where 0.7% had to undergo bypass
surgery (successfully). Magic Valley Regional Medical Center (MVRMC) in Twin
Falls, 10, implemented a program of providing PCI for acute coronary syndromes
in a rural setting without surgical backup starting in 2003 (25). It compared its
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outcomes with those of the ACC registry of 2004, which are considered the
standard of care. The distributions of door-to-balloon times were statistically
significant with that of MVRMC being lower than that of the ACC registry. The inhospital death rates were 1.96% for MVRMC and 1.16% for the ACC registry
(p=0.1446) indicated not significant difference. Only one patient had to be
transferred for open-heart surgery after the perforation of the left anterior artery.
The transport time to Boise was 100 minutes, and the surgery did not have any
complications.
In 2000, the New York State Department of Health, which has a Certificate of
Need system for limiting the number of hospitals in which CABG surgery and PCI
can be performed, began to allow a limited number of hospitals to perform
emergency (primary) PCI for patients with STEMI. By 2006, a total of 11
hospitals were certified to perform PCI without surgical backup (henceforth called
P-PCI centers). This study compares patient outcomes for patients with STEMI in
those hospitals with patient outcomes in full service (FS) cardiac hospitals
(hospitals that perform CABG surgery as well as P-PCI and elective PCI)" (table
4) (26). The PAM I-No SOS study showed that primary PCI in high-risk STEMI
patients in hospitals without on-site cardiac surgery is safe, effective and faster
than primary PCI after transfer to a surgical facility (31). Locally, the state of
Kentucky conducted a pilot study to investigate the soundness of allowing select
facilities in the state to perform primary PCI despite being devoid of onsite
emergency backup capabilities (4). It concluded that clinical outcomes were not
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different between the local hospitals and the national standard and that study
populations were similar to those of national PCI registries.
Table 4
P-PCI Center

FS - Center

In-hospital/30-day mortality

2.31%

1.91%

Same/Next day CABG

0.23%

0.69%

0.046

Emergency CABG

0.06%

0.35%

0.06

p-value

Cost Benefit of PCI vs. Thrombolysis
As early as 1994, the Mayo Clinic conducted a study to compare costs of
immediate PCI and thrombolytic therapy for acute coronary syndromes (44). The
Mayo Clinic's hypothesis was that thrombolysis followed by adjunctive medical
treatment was more cost-effective than angioplasty. However, the researchers
arrived at the conclusion that there was no difference in cost-effectiveness within
a twelve-month period. In 1993, the Health Technology Assessment Programme
in the UK embarked in a long-term cost-effectiveness analysis of primary
angioplasty taking the perspective of the UK's National Health System (NHS)
with the subsequent results being published in 2005 (45). Their results
consistently and convincingly demonstrated a clinical advantage of immediate
PCI over thrombolysis. No evidence was found suggesting that services should
be concentrated in to large hospitals in metropolitan areas despite evidence that
larger volumes of the procedure resulted in lower levels of mortality. The
economic evaluators compared PCI with thrombolytic therapy for people with
AMI; they found that PCI was more cost-effective than thrombolysis even when
taking into account variations in the cost of drugs and health status of the
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patients. Khot et aI., conducted a small prospective analysis of the costs related
to reducing the door-to-balloon time for STEMI patients at St. Francis Hospital
and Health Center (Beech Grove and Indianapolis, IN) (46). They concluded that
all of the financial benefits of reducing DTB in STEMI patients are obtained by
the payers both during initial hospitalization and after one-year follow-up.

Gap in the Knowledge Base
As detailed above, it is well established that PCI should be the advocated
management strategy for AMI patients, especially those experiencing a STEMI. It
is also well established that PCI is cost-effective when compared to thrombolysis
and that it is medically sound to allow hospitals without backup surgical
capabilities to perform primary PCI. The gap in the knowledge base is whether it
is cost-effective to allow hospitals without surgical backup capabilities to perform
PCI, when compared to only allowing hospitals with backup capabilities to
perform PCI. Therefore, the results of this thesis will push forward the knowledge
concerning primary PCI.
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CHAPTER III
METHODS

ST-elevation myocardial infarction (MI) is considered one the leading
causes of acute cardiac syndromes. During the last decade, many technological
and methodological developments have occurred in interventional cardiology that
is aimed to assist with this type of MI. Such progress has made percutaneous
coronary interventions (PCl's) safe and effective in the treatment of acute MI
(AMI), in particular STEMI. During this time, many studies have shown that PCI
produces significantly better outcomes than thrombolysis. Furthermore, these
studies suggest that an aggressive treatment of STEMI is the more effective way
to prevent deaths attributed to Ml's. As a result, the national guidelines
developed by the American Heart Association and the American College of
Cardiology advocates primary PCI as the preferred treatment for patients with
STEMI. However, a key aspect for the success of PCI is the door-to-balloon
time. Studies have consistently demonstrated a negative association with the
outcomes from a PCI and DTB time: the longer the DTB time, the less likely PCI
will be successful. During the last decade many interventional cardiologists and
public health administrators have promoted the idea of allowing regional
hospitals without open-heart surgery-on-site capabilities to perform primary PCI
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as one way to address this issue in rural areas. It was the objective of this study
to determine the cost-effectiveness of allowing selective regional hospitals
without surgical backup for coronary artery bypass to perform primary PCI. The
medical soundness of allowing selective regional hospitals without surgical
backup for coronary artery bypass to perform primary PCI was established in our
initial report from this pilot program.
"Cost-effectiveness analysis is a method designed to assess the
comparative impacts of expenditures on different health interventions ... based on
the premise that 'for any given level of resources available, society wishes to
maximize the total aggregate health benefits conferred.' The central measure
used in cost-effectiveness analysis is the cost-effectiveness ratio. Implicit in the
cost-effectiveness ratio is a comparison between alternatives. The costeffectiveness ratio for comparing the two alternatives is the difference in their
costs divided by the difference in their effectiveness, or CIE."
The measurement of effectiveness for the current study is the number of
deaths averted. The effectiveness estimates have been derived from a
systematic literature review of national prospective studies based on PCI
registries as well as our earlier study evaluating the KENTUCKY PILOT
PROJECT FOR PRIMARY PCI WITHOUT ONSITE CABG (4). Such studies
have shown that differences in effectiveness of PCI between the two alternatives
(allowing/not allowing these regional hospitals to perform primary PCI) were not
statistically significant). Five studies, from the literature review, were considered
to have relevance and deemed pertinent for the current study. They were
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selected by the author based on the study population, sample size, study design,
outcome variables of interest, and follow-up time. Specifically of interest were
studies that included mortality rates stratified by door to balloon time intervals,
complication rates due to the differing physiology of the patients and due to
catheterization, and the corresponding emergency surgery rates. The measures
of clinical complications comprised several major adverse coronary cardiac
events: stroke, bleeding, infarction size, and repeated PCI. Table 1 provides a
description on where these selected studies were conducted, type of study
design employed, and outcome measures evaluated. Clearly, most studies
favored a short door to balloon time. Also, many of the studies suggested that it
is efficacious to allow regional hospitals without surgical backup to perform
primary PCI. For example, the study "Safety In Numbers For Community
Hospitals Performing Emergency Angioplasty" from Johns Hopkins University
School of Medicine and its Heart and Vascular Institute found that the mortality
rate in nonsurgical hospitals to be 2.2% and not significantly different from the
mortality rate observed in hospitals equipped with open-heart surgical facilities.
Also from this study, the proportion estimates for a door-to-balloon time less than
or equal to 90 minutes was determined to be 44.8%. Similarly, our earlier report
evaluating the KENTUCKY PILOT PROJECT FOR PRIMARY PCI WITHOUT
ONSITE CABG found that there were no differences in mortality rates,
emergency surgery as a result from PCI, and door-to-balloon time between
regional non-surgical hospitals and national estimates from hospitals with open
heart surgery capabilities.
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Table 5. Studies used in the economic analysis.
Study

Local

Type of study

Outcomes

Audit

Mortality, OHS

Univ. of Florida, USA

Audit

Mortality, OHS

Mattichak

William Beaumont Hospital, USA

Audit

PCI complications

McNamara et al.

Yale Univ., USA

Moscucci et al.
Mishra et al.

Darwazah et al.

Makassed Hospital, Israel

K. Haan at al.

Cohort

Mortality, OBT

Univ. of Michigan, USA

Audit

Mortality, OHS

Queen Elizabeth Hospital, Australia

Audit

Mortality, OHS

Pilot, Cohort

Univ. of Louisville, USA

Mortality,OHS, OBT

Ong et al.

Changi General Hospital, Singapore

Review

Mortality, OHS

Rathore et al.

Yale Univ., USA

Cohort

Mortality, OBT

Seshadri et al.

Cleveland Clinic, USA

Audit

Mortality, OHS

Yang et al.

Mayo College of Medicine, USA

Audit

Mortality,OBT

Intervention Costs
The National Inpatient Sample (NIS) database contains all-payer data on
hospital inpatient stays from states participating in the Healthcare Cost and
Utilization Project (HCUP). The database consists of three tables with records
from the year 2005: inpatient records, hospital characteristics, and severity index.
One of the NIS main functions is to promote comparative studies on costs and
the use of hospital services. The NIS contains information on nearly eight million
hospital stays for the year 2005, which makes the NIS the largest database of allpayer inpatient observations. The inpatient records table contains one record per
inpatient admission with information about primary and secondary diagnosis,
primary and secondary procedures, patients' demographics, admission and
discharge status, total charges, and length of stay. The charge information is
collected on all patients regardless of payer; that is, it includes coverage
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information from patients covered by Medicare, Medicaid, private insurance, as
well as those who are uninsured. The hospital characteristics table has
information on 1,056 hospitals that comprise the sample. This table contains
information such as hospital ownership, size, teaching status, region,
metropolitan area, and hospital 10 that corresponds to records in American
Hospital Association database. The design of the sample is to approximate a
twenty percent sample of the U.S. community hospitals, which encompasses
specialty hospitals, public hospitals, and academic medical centers. The hospital
universe is defined by all hospitals that were open during any part of each
calendar year and were designated as community hospitals in the American
Hospital Association Annual Survey Database.
In determining costs, the inpatient table was first filtered to contain only
observations corresponding to a principal diagnosis of STEM!. This was
achieved by filtering by using the ICD-9 code 410. Hospital information was
added by linking this table to the hospital characteristic table using the hospital
10. Subsequently only observations from the Midwest and South were retained
to make cost more appropriate for the regional hospitals evaluated. From this
subset, observations corresponding to primary PCI were identified using the
procedures variables: the corresponding ICD-9 code used was 00.66, and all
non-PC I records were dropped. Then, observations corresponding to emergency
CABG were identified by using the ICD9 code 36.1X. Finally, cost estimates
were obtained for primary PCI only for facilities without onsite backup and for
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facilities with surgery on site capabilities. Table 2 summarizes the codes used to
obtain these costs.
Table 6. ICO-9 codes used to obtain relevant costs from the NIS dataset
Description

ICD-9

410

----_.

Acute Myocardial Infarction

0.66

Percutaneous transluminal coronary angioplasty

0.4

Procedure on single vessel

0.41

Procedure on two vessels

0.42

Procedure on three vessels

0.43

Procedure on four or more vessels

36.11

(Aorto) coronary bypass of one coronary artery

36.12

(Aorto) coronary bypass of two coronary arteries

36.13

Aorto) coronary bypass of three coronary arteries

36.14

(Aorto) coronary bypass of four or more coronary arteries

36.06

Insertion of non-drug-eluting coronary artery stent(s)

0.45

Insertion of one vascular stents

0.46

Insertion of two vascular stents

0.47

Insertion of three vascular stents

0.48

Insertion of four or more vascular stents

----~

Analysis
The current study was focused on Kentucky's policy on primary PCI. The
question of interest is "Is allowing hospitals without open heart surgical backup to
perform primary PCI cost effective?" The evaluation developed for this
assessment is based on a 3D-day decision-analytical model, which examines the
benefits and costs of two strategies: (1) performing primary PCI only in hospitals
with backup surgery and (2) performing primary PCI in both hospitals with and
without CABG capabilities (that meet the recommendations in Myers et al.). The
model displays the likelihood a patient having an acute myocardial infarction
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experiences all plausible and relevant c events (See figure 1 and table 3). The
structure of the model, presented in figure 1, was developed using evidence from
a systematic literature review of clinical effectiveness of primary PCI. The model
represents the pivotal states that would determine both the costs and
effectiveness of the alternative treatment options for people experiencing an
acute myocardial infarction. The economic evaluation focused on estimating the
incremental cost effectiveness ratio (ICER) of allowing the regional hospitals to
perform primary PCI. The perspective of the study is from the payer. As a
consequence, capital costs, training costs, and overhead costs were not included
in this study. Uncertainty about the model parameters was investigated through
employing sensitivity analysis techniques, which tested how the assumptions
affected the outcomes and sensitivity of each variable. As a result, the model for
this study includes two main pathways in the analysis tree for treatment of acute
myocardial infarction (AMI). It shows that patients suffering from an acute
myocardial infarction have two options: (1) only be allowed to receive a primary
PCI in a hospital with open-heart surgery backup or (2) also (for those in rural
areas) being allowed to receive a primary PCI in a hospital without CABG
capabilities. When an individual experiences an AMI, they will usually be
transported to nearest hospital. This primary center may be equipped with
surgical-on-site capabilities or, if in a rural area, may be a hospital without
surgical backup. A key aspect in the treatment of AMI, in particular of STEMI, is
the response time of the medical facility. In particular, the door-to-balloon time
(DBT) is critical in the effectiveness of primary PCI, in particular with respect to
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mortality and morbidity. OBT refers to the time from the moment the individual
arrives to the hospital to the moment when the catheter crosses the culprit lesion
and a balloon is inflated to open up the artery's blockage. Based on many
studies, the American Heart Association and the American College of Cardiology
have established as a guideline that OBT is not to exceed 90 minutes. This
means that the proportion of patients with a door-to-balloon time greater than
ninety minutes is associated with a higher rate of mortality and unsuccessful PCI.
Clearly, requiring that a person suffering from an AMI be transported to a facility
with surgical backup capabilities increases and is associated with increases in
OBT. Thus, allowing individuals in more remote areas to receive a PCI at a
regional facility may be beneficial.
It is well established that medical interventions, even those successfully
performed, do not guarantee a successful outcome. Primary PCI can have two
direct outcomes regardless of door to balloon time: mortality and intervention
survival. Having survived primary PCI occurs in two health states: successful
PCI and complications. Patients who survive the intervention may have
complications requiring emergency open-heart surgery or minor complications
related to their physiology. Those patients who do not require emergency
surgery are considered as lives saved with utility value of 1. Alternatively, the
complications lead to emergency coronary by-pass surgery with resulting
outcomes of mortality or success as a saved life.
The cost-effectiveness ratios are computed by taking the difference in
costs from the two clinical facilities for primary PCI while the denominator is
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obtained by the difference in number of deaths prevented on each branch.
Sensitivity analysis was conducted for the estimated proportions of door to
balloon time and complications with respect to the hospital categories. In
addition, estimated costs for primary PCI and emergency coronary bypass
surgery are analyzed up to a two-fold increase for both branches.
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Table 7, Model's probabilities
Probabilities
I2SDBTs
pLDBTs
pSDB
~~T
~a____~____~
pLDBTa
pM_SDBTs
pM_LDBTs
pM_SDBTa
pM_LDBTa

Definitions
S art Door to Balloon Time for surgical hos(:!itals «=90 min)
Long Door to Balloon Time for surgical hospitals (>90 min)
Short Door to Balloon Tim for all hospitals «=90 min)
Long Door to Balloon Time for all hospitals (>90 min)
Mortality and Short Door to Balloon Time for surgical hospitals
Mortality and Long Door to Balloon Time for surgical hospitals

S Ps
pSSPs

Mortality and Short Door to Balloon ime for all hospitals
Mortality and Long Door to Balloon Time for all hospitals
Complications after PCI for surgical hospitals
Complications after PCI for all hospitals
Failed PCI given SDBT for surgical hospitals
Successful PCI given SDBT for surgical hospitals

pSPCs
pSPMs

PCI complications given SDBT for surgical hospitals
PCI mortality given SDBT for surgical hospitals

pCPCls
pCPCla

pLFP
=
s~

pLSPs
RLPCs
pLPMs
pSFPa
pSSPa
pSPCa
pSPMa
pLFPa
pLSPa

____~______

_-...---------.

a'ied PCI g'ven LDBT for surgical hospitals
Successful PCI given LDBT for surgical hospitals
-:------.
PCI complications given LDBT for surgical hospitals
PCI mortality given LDBT for surgical hospitals
Failed PCI given SDBT for all hospitals
Successful PCI given SDBT for all hospitals
PCI com(:!lications given SDBT for all hospitals
PCI mortality given SDBT for all hosptitals

Failed PCI given LDBT or all hospitals
Successful PCI given LDBT for all hospitals
--~--~~-------,
RLP~
C~
a------~~--~
PCI complications given LDBT for all hosRitals
PCI mortality given LDBT for all hospitals
pLPMa
Emergency Surgery given SDBT for surgical hospitals
I2SESS
pSNEs
Not Emergency Surgery given SDBT for surgical hospitals
(:!LESs
Emergency Surgery given LDBT for surgical hospitals
pLNESs
Not Emergency Surgery given LDBT for surgical hospitals
RSES~
S~
a______~____
Emergency Surgery given SDBT for all hospitals
Not Emergency Surgery given SDBT for all hospitals
pSNESa
--~-~Emergency Surgery given LDBT for all hosRitals
psLESa
pLNESa
Not Emergency Surgery given LDBT for all hospitals
pSESSs _ _ _ _~_ Emergency Sur ery Success give SDBT 0 surgical ospitals
pSESFs
Emergency Surgery Failure given SDBT for surgical hospitals
~-Emergency Surgery Success given LDBT for surgical hospitals
RLESSs
pLESFs
Emergency Surgery Failure given LDBT for surgical hospitals
Emergency Sur ery Success given SDBT for all hos itals _ _....
pSESSa
pSESFa
Emergency Surgery Failure given SDBT for all hospitals
'7:'":"-~-:------""
pLESSa_ _ _ _ __
ergency Su gery Success given LDBT for all
hosRitals

pLESFa

Emergency Surgery Failure given LDBT for all hospitals
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CHAPTER IV
RESULTS

This study was designed to extend previous findings from our earlier
report, the Kentucky Pilot Project for Primary PCI without On site CABG; which
demonstrated that there were no statistical differences in outcomes between
facilities with onsite emergency backup capabilities and those that lacked such
capabilities when compared to established values. With the exception that
T JSCH had a higher proportion of individuals who received their CABG in less
than 90 minutes. Tables 3 and 4 show the results from the original study, which
suggests the there is no significant difference in any of the outcome variables
studied between facilities with and without onsite emergency open heart surgery
capabilities.
Since costs estimates were obtained from the 2005 National Inpatient
Sample (NIS), the NIS data set was statistically investigated for many of the
variables that were evaluated in the Kentucky Pilot Project for Primary PCI
without On site CABG report. To allow for a more direction comparison with the

earlier report, the NIS was initially filtered to include only observations in the
Midwest and Southeast. This resulted in a sample of 7,586 subjects who
received an emergency PCI. A majority of the cases were obtained from facilities
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with emergency backup capabilities (n=7 ,248); while only 338 of the observations
came from individuals seen at facilities without open-heart surgery capabilities.
Table 3 shows the main demographic characteristics stratified by facility type. In
the NIS population the mortality rate was 2.8% for individuals seen at hospitals
with onsite CABG capabilities, while the mortality rate was 3.5% for individuals
seen at hospitals, which did not have onsite CABG capabilities.

Table 8. Comparisons of T JSCH Outcome Measures and the national values.
Outcome
Mortality
- In-hospital, n (%, 95% CI)
- WI onsite CABG
- W/O onsite CABG
Door-to-Bailoon Time
- WI onsite CABG
- W10 onsite CABG
Door-to-Bailoon Time < 90 minutes
- n/Total (%)
- WI onsite CABG
- W/O onsite CABG
Cardiac Arrests
- PCI Related , n (%, 95% CI)
- WI onsite CABG
- WIO onsite CABG
Emergency OH Surgeries Performed,
- PCI Related, n (%, 95% GI)
- WI onsite GABG
- W/O onsite GABG

TJSCH
(n 158)

Reference
Values

p-value

4 (2.5, 0.7-6.4)

2.2%
2.2%

0.9186 (NS)
0.9186 (NS)

92.7 mins

100.4 mins
94.0 mins

0.0728 (NS)
0.7630 (NS)

90/158 (57.0)

44.8%
44.8%

0.0028 (*)
0.0028 (*)

o (0.0, 0.0-2.3)

0.4%
N/A

1.0000 (NS)
N/A

o (0.0, 0.0-2.3)

0.4%
0.3%

1.0000 (NS)
1.0000 (NS)

=

About thirty-three percent of the patients were female in the hospitals with
open-heart surgery capabilities, while in the hospitals without open-heart
capabilities the proportion of female patients was about thirty-seven percent.
The mean age for PCI patients in emergency-surgery capable hospitals was
62.48 years, compared to a mean age of 63.08 patients in non-emergency-
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surgery capable hospitals. The proportion of patients needing emergent CABG
after unsuccessful PCI was 2.47% in open-heart-surgery capable facilities while it
was only 0.8% in facilities without open-heart-surgery capabilities. In addition,
the mean length of stay was very similar for facilities with and without CABG
capabilities: 4.36 days and 4.41 days respectively. None of these characteristics
were statistically significantly different between individuals seen at these two
types of facilities .
Table 9. Comparisons of EMRMC Outcome Measures and the national values.
Outcome

EMRMC
(n 77)

Reference
Values

p-value

2.2%
2.2%

1.0000 (NS)
1.0000 (NS)

100.1 mins

100.4 mins
94.0 mins

0.9524 (NS)
0.2167 (NS)

28/56 (50.0)

44.8%
44.8%

0(0.0,0.0-4.7)

0.4%
N/A

1.0000 (NS)
N/A

0(0.0,0.0-4.7)

0.4%
0.3%

1.0000 (NS)
1.0000 (NS)

=

Mortality
- In-hospital, n (%, 95% CI)
- WI onsite CABG
- W/O onsite CABG
Door-to-Balloon Time
- WI onsite CABG
- WIO onsite CABG
Door-to-Balloon Time < 90 minutes
- n!Total (%)
- WI onsite CABG
- W/O on ite CABG
Cardiac Arrests
- PCI Related, n (%, 95% CI)
- WI onsite CABG
- W10 onsite CABG
Emergency OH Surgeries Performed,
- PCI Related, n (%, 95% CI)
- WI onsite CABG
- WIO onsite CABG

To provide a more comprehensive evaluation of the NIS data set, patients
not requiring emergency CABG following emergent PCI were compared between
the two types of facilities (Table 3). For hospital with open-heart-surgery
capabilities, the mortality rate was 2.69%, the proportion of female patients was
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33.56% , the mean age was 62.42 years, the mean length of stay was 4.1 days,
and the mean total charges was $54,675. For hospitals without open-heartsurgery capabilities, the mortality rate was 3.58%, the proportion of female
patients was 37.31 %, the mean age was 63.11 years , the mean length of stay
was 4.23 days, and the mean total charges was $48,234. The only
characteristic, which was significantly different between these two groups, was
total charges.
Table 10. NIS Outcome Measures by Primary Hospital Open Heart Surgery Capabilities
Outcome

WI onsite CABG

WIO onsite CABG

p - value

Mortality

2.8% (2.4 - 3.2)

3.5% (1.6 - 5.5)

0.4370

Female

33.34% (32.3 - 34.4)

36.96% (31.8 - 42.1)

0.1653

Age

62.48 ± 13.22

63.08 ± 13.46

0.3600

Emergency CABG

2.47% (2.1 - 2.8)

0.8% (0 - 1.9)

0.0632

Length of Stay

4.36 ±4.12

4.41 ± 4.15

0.8400

Similarly, patients requiring emergency CABG following emergent PCI
were compared between the two types of facilities (Table 4). For hospital with
onsite CABG capabilities, the mortality rate was 8.38% , the proportion of female
patients was25% , the mean age was 62 .73 years, the mean length of stay was
11 days, and the mean total charges was $134,498. For hospitals without onsite
CABG capabilities, the proportion of mortality was 0% , the proportion of female
patients was 0%, the mean age was 64 .66 years, the mean length of stay was 10
days, and the mean total charges was $107,915 . The mortality rate and the
proportion of females were significantly different between hospitals with and
without onsite CABG capabilities .
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Table 11. Patients who did not have emergency CABG
Outcome
Mortality
Female
Age
Length of Stay
Total Charges
# Stents

----,

o
1

2
3
4

WI onsite CABG
2.69°/~ 2.3 - 3.1)
33.56% (32.4 - 34.6)
6
.27
4.10 ± 3.39
$ 54,675 ± 29,987

WIO onsite CABG
3.58 (1.6 - 5.6)
37.31 (32.1 - 42.5)
63.11 ± 13.57
4.23 ± 3.07
$ 48,234 ± 26.359

1,093
3,740
1503
500
233

63
188
57
23
4

p - value
0.3027
0.1561
0.3691
0.4393
< 0.0001 *

Table 12. Patients who had emergency CABG

WI onsite CABG

WIO onsite CABG

p - value

Mortality

8.38% (4.3 -12.4)

0%

Female

25%(18.1-31.5)

0%

< 0.0001
< 0.0001

62.73 ± 11.82

64.66 ±8.74

0.7780

11 ± 6.3

10 ± 3.22

$ 134,498 ± 69,791

$ 107,915 ± 34,099

Outcome

Length of Stay

# Stents
3

0
1

25

0

2

4

0

3

5

4

0

Furthermore , kernel density estimation was used to estimate the
probability density curve for age, length of stay and total charges. For patients
who did not require emergent CABG following PCI, the probability density
function for age tends to be uniform between the ages of 45 and 85 years old for
both types of facilities. For patients requiring emergent CABG after PCI , the pdf
for facilities without onsite CABG capabilities is lightly skewed to the left with a
peak about 69 years while the cure for facilities with onsite CABG capabilities
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has less kurtosis and is less skewed . These results would support normality and
allow us to use parametric methods.
Figure 1
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The estimated curve for length of stay is skewed to the right, which was
expected as this type of data tends to follow a lognormal or a gamma distribution.
For patients who did not have emergency open heart surgery, the curve peaks at
about 3 days. However, the curve corresponding to facilities without onsite CABG
capabilities has less kurtosis than that correspond to facilities with onsite CABG
capabilities. As expected from the resulting statistics , the curves for those
patients who had emergent CABG peak much more to the right. For hospitals
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with onsite open heart-surgery capabilities , the curve peaks near nine days and
is severely skewed to the right. On the other hand, the curve for hospitals
without onsite CABG peaks near twelve days and is slightly skewed to the left.
Figure 3
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Cost Estimates
The main parameter obtained from the NIS data set for the current
analysis is total charges for t.he two approaches , PCI and PCI+CABG . The
estimated curves for those patients receiving only emergent PCI are both lightly
skewed to the right, with the curve for facilities without onsite CABG capabilities
peaking near $33 ,000 and kurtosis of 1.6; while the curve for facilities with onsite
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CABG capabilities peaking further to the right at about $42,000 and kurtosis of 3.
For patients having both emergent PCI and emergent CABG , the curve for total
charges in facilities without onsite CABG capabilities was heavily concentrated
near $93,000 while the curve for hospitals with onsite CABG is more evenly
dispersed with peak at about $98,000.
Figure 5
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Probability Estimates
Probabilities were estimated from studies that evaluated the relevant
outcomes of interest. In addition the sample size and study design of the reports
were evaluated as well to evaluate their usefulness. To provide precise
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estimates of these probabilities, traditional meta-analysis techniques were used.
That is, the sample sizes for each study were aggregated (N), the numbers of
cases were aggregated (n), and then the ratio was computed (n/N). Table 5
displays the estimated probabilities for the outcomes of interest for hospitals with
onsite CABG capabilities. These estimates are listed along with the study from
which they are derived along with the estimated 95% confidence interval.
Similarly, table 6 shows the corresponding estimated probabilities for facilities
without onsiteCABG capabilities. The estimate for a door-to-balloon time less
than ninety minutes for hospitals without open-heart-surgery capabilities is 0.551
and 95% confidence interval of (0.485 - 0.618), while the corresponding estimate
for facilities with onsite CABG capabilities is 0.448.
Table 7 displays the variables that were incorporated in the model. Figure
1 shows the model along with its corresponding components. From the literature
review, a key variable for successful PCI outcomes is a door-to-balloon time less
than 90 minutes. The estimated proportion was estimated to be 55.2% for
hospitals with onsite CABG 50.0% when both types of facilities were considered.
The probability of PCI failure for each door-to-balloon cut-off value was
constituted by the probability of death corresponding to the specific cut-off value
as well as the probability of complications, which was clearly dependent on the
door-to-balloon time. This is contrasted with the probabilities for emergency
CABG; these values did not depend on door-to-balloon time but rather on the
individual characteristics of the patient.
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The estimated costs are calculated from a third-party payer point of view
from public total charges records rather than net payments. Since the latter
payment is not a public record and considered proprietary information they are
not available for analysis. For hospitals without onsite CABG capabilities the
estimated cost for emergency PCI is $48,244 with a standard deviation of
$26359. In contrast, facilities with onsite CABG capabilities had a mean total
cost for emergent PCI of $54,675 and a standard deviation of $29,987.
Cost-Effectiveness
To evaluate the cost-effectiveness of allowing regional hospitals to
perform primary PCI the decision model (Figure 1) had to be rolled back. That is,
the joint probability of each outcome (e.g., DBT < 90 minutes with no adverse
effects) was multiplied by the utility of the outcome (probability of death) and
summed over all outcomes; these values were then stratified by alternatives. The
incremental cost-effectiveness then was evaluated by dividing the incremental
costs by the incremental effectiveness.
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Table 12. Estimates for Hospitals with onsite CABG
Outcome
OTB<90 min
Thom et al. (47)
Proportion of

BT < 90 min and 95% CI

n

N

N/A

N/A

44.8%

Mortality when OTB < 90 min
McNamara et al. (48)
Rat ore et al. ( 4)
Yang et al. (4)
Total
Mortality Rate and 95% CI

876
909
7
1792
3.25%

29222
25359
479
55060
3.10%-3.40%

Complications after PCI
Mattichak et al. (49)
Rate of Complications and 95% CI

357
4.80%

7426
4.30%-5.30%

Emergency CABG
Oarwaza e I. ( )
Haan at al. (2)
Moscucci et al. (3)
Yang et al. (4)
Mattichak e al. (49)
Total
Rate of Emergency CABG and 95% CI

31
3352
49
20
20
3472
0.33%

1200
1042864
2303
6577
7426
1060370
0.31 %-0.34%

155

1200

536
10
2
6
709
15.2%

3352
49
20
29
4650
14.2%-16.3%

Mortality after E. CABG
Oarwaza AK et al. (1)
Haan at al. (2)
Moscucci et al. (3)
Yang et al. (4)
Seshadri et al. (7)
Total
Mortality Rate and 95% CI

When the cost-effectiveness model was rolled back, the alternative to
allow Regional Hospitals as well to perform primary PCI dominated the other
alternative of Only Allowing Hospitals with Onsite CABG to perform PCI. That is,
allowing regional hospitals to perform primary PCI both incur fewer costs; while
also averting more deaths (Table 14). Therefore, it "dominates" the other
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alternative since it performs better on all attributes studied. The incremental costeffectiveness ratio of allowing regional hospitals to perform PCI was -$41 K per
death averted, when compared to the option of Only Hospitals with Onsite CABG
(Table 14). That is, allowing regional hospitals to perform PCI will save $41 K per
death averted. Therefore, establishing this alternative as a cost-effectiveness
way in which to provide primary PCI in the State of Kentucky and providing
further evidence to allow regional hospitals (that meet the recommendations
outlined in Myers et al) to perform primary PCI.

Table 13. Estimates for Hospitals wlo onsite CABG

n

N

118

214

55.1%

48.5% - 61.8%

Myers et al.

1

235

K.J. Mishra (1)

o

778

Outcome
DBT <90 min
Myers et al.
proportion and 95% CI
Mortality and DBT < 90 min

1013

Total
proportion and 95% CI

0.0 - 0.5%

Complications after PCI
Myers et al.
proportion and 95% CI

60

235

25.5%

19.9% - 31.1%

Emergency CABG
K.J. Mishra (1)
Sea Hing Ong et al. (2)

o
o

778
,-.--~~~--

259

Myers et al.

235

Total

1272

proportion and 95% CI

0.08%

0.0% - 0.23%

Mortality after E. CABG

235

Myers et al.
proportion and 95% CI

0.4%
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0.0% -1.2%

Sensitive Analysis

The decision to allow regional hospitals to perform PCI was only sensitive to
one variable in the model (the cost of PCI at Regional hospitals, cPa). As this cost
increases, the cost per death averted associated with allowing regional hospitals to
perform primary PCI also increases making this alternative less attractive. The
decision is sensitive within the plausible range of values for this variable. If the cost
of PCI of regional hospitals increases by $5000 (representing a 9.2% increase from
baseline, from $54,300 to $59,300) allowing regional hospitals to perform primary
PCI would not be cost effective.
Table 14. Cost Effectiveness Analysis
Incremental Comparison
Strategy

Only Hospitals with onsite CABG

$54,687.38 K

954

All PCI equipped Hospitals

$54,401.25 K

961

44

-$286.19 K

7

-$41,164.25

Table 15. Model specifications in summary
Variable

Value

Variable

Value

RSDBTs
pLDBTs
pSDBTa
pLDBTa

0.448
0.552
0.50

RLFPa
pLSPa
pLPCa
pLPMa

0.094
0.906
0.574
0.426
0.003
0.997
0.003
0.997
0.003
0.997
0.003
0.997
0.848
0.152
0.848
0.152
0.855
0.145
0.855
0.145
$54,675
$54,389

pM~SDBTs

pM_LDBTs
pM_SDBTa
pM_LDBTa ,
pCPCls
pCPCla
pSFPs
pSSPs
pSPCs
pSPMs
pLFPs
pLSPs
pLPCs
pLPMs
pSFPa
pSSPa
pSPCa
pSPMa

pSESs
pSNEs
pLESs
pLNESs
pSESa
pSNESa
pLESa
pLNESa
pSESSs
pSESFs
pLESSs
pLESFs
pSESSa
pSESFa
pLESSa
pLESFa
CPs
CPa

0.058
0.032

0.054
0.078
0.922
0.615
0.385
0.106
0.894
0.453
0.547
0.086

0.372

45

Table 16. Sensitivity Analysis of PCI cost at hospitals with onsite CABG
CPs
54675

59645.45

64615.91

69586.36

74556.82

79527.27

84497.73

89468.18

94438.64

99409.09

Strategy

Cost

Eff

Regional Hospitals as Well

$54,410

1

$56,450

Only Hospitals with Onsite CABG

$54,686

1

$57,292

Regional Hospitals as Well

$54,543

$56,588

Only Hospitals with Onsite CABG

$59,656

$62,499

Regional Hospitals as Well

$54,677

$56,727

Only Hospitals with Onsite CABG

$64,626

$67,705

Regional Hospitals as Well

$54,811

$56,866

Only Hospitals with Onsite CABG

$69,596

1

$72,912

Regional Hospitals as Well

$54,945

1

$57,005

Only Hospitals with Onsite CABG

$74,565

$78,118

Regional Hospitals as Well

$55,079

$57,144

Only Hospitals with Onsite CABG

$79,535

$83,325

Regional Hospitals as Well

$55,212

Only Hospitals with Onsite CABG

$84,505

$88,531

Regional Hospitals as Well

$55,346

$57,421

Only Hospitals with Onsite CABG

$89,475

1

$93,738

Regional Hospitals as Well

$55,480

1

$57,560

Only Hospitals with Onsite CABG

$94,444

$98,944

Regional Hospitals as Well

$55,614

$57,699

Only Hospitals with Onsite CABG

$99,414

$104,151

1

Regional Hospitals as Well

109350

C/E

ICER

(Dominated)

(Dominated)

(Dominated)

(Dominated)

(Dominated)

(Dominated)

$57,283
(Dominated)

(Dominated)

(Dominated)

(Dominated)

$57,838

Only Hospitals with Onsite CABG

$104,384

Regional Hospitals as Well

$55,881

Only Hospitals with Onsite CABG
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$109 ,357

1

$57,977

1

$114,564

(Dominated)

(Dominated)

Table 17. Sensitivity Analysis of PCI cost at all hospitals
CPa
54389

59333.45

64277.90

69222.36

74166.81

79111 .27

84055.72

89000.18

93944.63

98889.09

103833.54

108778

Cost

Strategy

Eff

CIE

Regional Hos itals as Well

$54K

0.96

Only Hospitals with Onsite CABG

$55K

0.95

$57,292

Only Hospitals with Onsite CABG

$55K

0.95

$57,292

$59K

0.96

$61 ,441

Onl Hospitals with Onsite CABG

$55K

0.95

$57,292

Regional Hospitals as Well

$64K

0.96

$66,431

Only Hospitals with Onsite CABG

$55K

0.95

$57,292

Regional Hospitals as Well

$69K

0.96

$71 ,422

Only Hospitals with Onsite CABG

$55K

0.95

$57,292

Regional Hospitals as Well

$74K

0.96

$76,413

Only Hospitals with Onsite CABG

$55K

0 .95

$57,292

Regional Hospitals as Well

$78K

0.96

$81,404

Only Hospitals with Onsite CABG

$55K

0.95

$57,292

Regional Hospitals as Well

$83K

0.96

$86,395

Only Hospitals with Onsite CABG

$55K

0.95

$57,292

Regional Hospitals as Well

$88K

0.96

$91,386

Only Hospitals with Onsite CABG

$55K

0.95

$57,292

Regional Hospitals as Well

$93K

0.96

$96,377

Only Hospitals with Onsite CABG

$55K

0.95

$57,292

Regional Hospitals as Well

$98K

Only Hospitals with Onsite CABG

$55K

0.95

$57,292

Regional Hospitals as Well

$103K

0.96

$106,359

Only Hospitals with Onsite CABG

$55K

Regional Hospitals as Well

$101,368

(Dominated)

$485,435

$1 ,000,518

$1 ,515,601

$2,030,684

$2,545,767

$3,060,849

$3,575,932

$4,091 ,015

$4,606,098

$5,121 ,181

$57,292
$111,350
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ICER

$5,636,264

Table 18. Sensibility Analysis of proportion of DBT<90 min. at hospitals with onsite CABG
pSDBTs
0.298

0.3478333

0.3976666

. 0.4475

0.4973333

0.5471666

0.597

Strategy

Cost

Eft

CtE

Regional Hospitals as Well

$54.4K

0.96

$56,450

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,545

Regional Hospitals as Well

$54.4K

0.96

$56,450

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,461

Regional Hospitals as Well

$54.4K

0.96

$56,450

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,377

Regional Hospitals as Well

$54.4K

0.96

$56,450

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,293

Regional Hospitals as Well

$54.4K

0.96

$56,450

Only Hospitals with Onsite CABG

$54.7K

0.96

$57,209

Regional Hospitals as Well

$54.4K

0.96

$56,450

Only Hospitals with Onsite CABG

$54.7K

0.96

$57,126

Regional Hospitals as Well

$54.4K

0.96

$56,450

Only Hospitals with Onsite CABG

$54.7K

0.96

$57,043
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ICER

(Dominated)

(Dominated)

(Dominated)

(Dominated)

(Dominated)

(Dominated)

(Dominated)

Table 19. Sensibility Analysis of proportion of DBT<90 min . at all hospitals
pSDBTa

Strategy

Cost

CIE
$56,527

0.33

0.385

0.44

0.495

0.55

0.605

0.66

ICER

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,292

Regional Hospitals as Well

$54.4K

0.96

$56,502

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,292

Regional Hospitals as Well

$54.4K

0.96

$56,477

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,292

Regional Hospitals as Well

$54.4K

0.96

$56,452

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,292

Regional Hospitals as Well

$54.4K

0.96

$56,427

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,292

Regional Hospitals as Well

$54.4K

0.96

$56,402

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,292

Regional Hospitals as Well

$54.4K

0.97

$56,377

Only Hospitals with Onsite CABG

$54.7K

0.95

$57,292
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(Dominated)

(Dominated)

(Dominated)

(Dominated)

(Dominated)

(Dominated)

(Dominated)

CHAPTER V
CONCLUSION

The current study was based on the results obtained by Myers and his
colleagues in their report Kentucky Pilot Project for Primary PCI without Onsite

CABG whose purpose was to investigate whether it was medically sound to allow
select facilities in Kentucky to perform primary PCI even when lacking onsite
emergency CABG capabilities. Because the former report established no
statistically difference in outcomes between facilities with and without open-heart
surgery backup, this study extended the former report by investigating how costeffective it is to allow the latter hospitals to perform emergency PCI given that
these facilities meet recommendations concerning screening criteria, surgeons'
experience, and facility's volume (table 1).
A careful literature review and meta-analysis resulted in robust estimates
for event rates used in the model. However, the pilot study on which the
previous report was based did not collect data concerning costs and
expenditures or related to quality of life of the patients. For this reason, a dataset
from the National Inpatient Sample 2005 was used to obtain cost estimates. To
verify that the cost estimated from this data set were relevant, the dataset was
explored for demographic characteristics using classical numerical and graphical
statistical methods. The resulting sample from this data set was similar in
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characteristics and outcomes such as age, number of stents used, length of stay,
and mortality rate to samples used in the literature review studies, meta-analysis,
and Kentucky pilot study on primary PCI.
Since the pilot study from which the efficacy data was obtained was
devoid of costs information, the National Inpatient Sample from 2005 was used to
obtain estimates of costs from total charges to patients. The reason to use total
charges as a surrogate to costs is that the latter are considered proprietary
information to insurance companies; hence, they are not readily available in the
United States. In addition, costs related to expenditures incurred for
transportation or incurred by the patient's personal care-giver (e.g. relative or
spouse) during the hospitalization were not estimated and therefore not included
in the cost-effectiveness analysis. The time lag between the records of the cost
data and the clinical trial data is lightly lengthy, and no cost adjustment (Le.,
discounting) was made to evaluate the 2005 currency in 2009 dollars. More
sophisticated analyses in the future may require a cost-adjustment to estimates
to 2009 or 2010 dollars, or they may collect cost data and all other variables
concurrently. Hence, this limitation may undermine the internal validity of the
results from the cost effectiveness analysis and its associated results.
The Kentucky Pilot Project for Primary PCI without On site CABG did not
collect quality of life data from patients or patients' care-giver(s).

For this

reason, the current study was based on cost per death adverted instead. Quality
of life data from patients such as preference on proximity of the facility providing
PCI, reduction on door-to-balloon time, and access to primary care provider
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could have increased the cost-effectiveness of allowing facilities without onsite
CABG capabilities to perform emergent PCI. Also, measurements on preference
on outcomes such as presence or lack of post-procedure complications, speedier
recovery given a shorter door-to-balloon time, or even need of quick delivery
emergent CABG. Furthermore, determining whether delivery of emergent PCI in
regional hospital rather than transfer to an distant urban facility would facilitate
access to a loved one, and this in turn could affect the quality of life of the
patient.
Another issue at hand when implementing the delivery of emergent PCI at
regional hospital is the use and allocation of resources in these facilities. This
study did not measure how this implementation could have affected the allocation
of resources such as the need to hire more medical staff or the reallocation of
current medical staff from one unit to another. If the delivery of emergent PCI by
regional hospitals incurs in the hiring of more medical staff, this could bring about
economical development to the region surrounding the hospital; however, this
could also mean an increase in costs of emergent PCI and a possible change in
the results of this study. Because the recommendations about the quality of care
include the need that interventional cardiologist in charge of emergent PCI keeps
a relatively high volume of procedures per year, the chief cardiologist in a
regional hospital may have to commute several times a month to an urban
hospital in order to meet the volume recommendations. Another byproduct of
these recommendations is that possible need to extend PCI delivery to non-

52

emergent cases in order to meet facility's volume recommended to keep a highly
competent medical staff.
Sensitivity to the cost of PCI at regional hospitals was observed in the
model. A mere increase of 9.2% or $5,000 from baseline in this variable
increased the cost per death adverted. This means that the decision is sensitive
within the plausible range of values for this variable. Consequently, allowing
regional hospitals to perform primary PCI could become non-cost-effective easily.
A heart attack or myocardial infarction (MI) is a serious detrimental event
because deprivation of blood to the heart muscle causes damage or possibly
death to the heart's tissues known as myocardium, which carry long-term
negative health conditions. It is been well established that the longer the heart is
deprived of blood, the more heart muscle is damaged and killed. The maxim
cardiologists follow is that time saved is heart saved; thus, establishing the need
to open the coronary arteries occluded as quickly as possible. For this reason a
short door-to-balloon time is a key aspect for PCI to be successful. Allowing
regional hospitals to perform emergent PCI is a means to achieve the goal of a
door-to-balloon time less than ninety minutes for everyone suffering a heart
attack. Many clinical studies have shown that shorter door-to-balloon time leads
to shorter average lengths of stay in the hospital, lower rates of reinfarction, and
lower rates of reocclusion.
The current study has several implications for the public health policies
implemented in the state of Kentucky, which must be based on the most current
evidence. In this case, the latest evidence supports allowing primary PCI to be
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performed at select facilities without onsite surgical backup. By allowing primary
PCI to be performed at select facilities without surgical backup, access to PCI
(the preferred method of reperfusion) is expanded to about forty-four percent of
the population in the state of Kentucky that are routinely served by these
facilities. As a result, the state of Kentucky also makes further progress in
reducing geographical health disparities, one of its main healthcare initiatives.
Expansion of primary PCI to select facilities without onsite CABG capabilities
may also increase the proportion of heart attack victims receiving PCI within the
optimal door-to-balloon time of ninety minutes and thereby improving the quality
of health outcomes of the population. These facilities are nearer to where the
patients and their family members live; making their recovery process and time
more comfortable by having their spouses and loved ones around for comfort
and support. Similarly, costs associated with visits and transportation will
decrease as well as costs associated with productivity loss.
As detailed before in this study, it is well established that PCI is consider
the superior management strategy for AMI patients, especially those
experiencing a STEM!. It is also well established that PCI is cost-effective when
compared to thrombolysis and that it is medically sound to allow hospitals without
backup surgical capabilities to perform primary PCI. This study had filled the gap
in the knowledge about the cost-effectiveness of allowing hospitals without
surgical backup capabilities to perform PCI, when compared to only allowing
hospitals with backup capabilities to perform PCI in the state of Kentucky.
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Therefore, the results of this thesis have pushed forward the knowledge
concerning primary PCI.
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